Toll-like Receptor-4 Is Up-Regulated in Hematopoietic Progenitor Cells and Contributes to Increased Apoptosis in Myelodysplastic Syndromes

Christos I. Maratheftis, Evangelos Andreakos, Haralampos M. Moutsopoulos, and Michael Voulgarelis

Abstract

Purpose: To investigate the function and expression of Toll-like receptors (TLR) in bone marrow cells of myelodysplastic syndrome (MDS) patients and to examine their involvement in the apoptotic phenomenon characterizing MDS hematopoiesis.

Experimental Design: TLR mRNA and protein expression was investigated in bone marrow cell populations of MDS patients and controls. TLR-4 ability to recognize lipopolysaccharide and up-regulate self mRNA and protein expression was examined. Tumor necrosis factor involvement in the constitutive and lipopolysaccharide (LPS)-induced TLR expression was also evaluated. Possible correlation between TLR-4 overexpression and apoptosis was investigated by simultaneous staining with Annexin V and TLR-4.

Results: TLR-2 and TLR-4 are expressed in almost all bone marrow cell lineages including megakaryocytes, erythroid cells, myeloid precursors, monocytes, and B lymphocytes and are up-regulated in MDS patients compared with controls. In hematopoietic CD34+ cells, TLR-4 is also expressed and significantly up-regulated at both the mRNA and protein levels. Treatment with an anti–tumor necrosis factor antibody reduces both constitutive and LPS-induced TLR-4 levels. Increased TLR-4 expression correlates with increased apoptosis as TLR-4 is almost exclusively found in apoptotic bone marrow mononuclear and CD34+ cells. The addition of the TLR-4 ligand LPS further enhances the apoptosis of these cells.

Conclusions: TLR-4 and other TLRs are significantly up-regulated in MDS patients whereas TLR-4 is involved in promoting apoptosis, possibly contributing to MDS cytopenia.

The Toll-like receptors (TLR) are members of a conserved family of type I transmembrane receptors characterized by an intracellular signaling domain homologue to the interleukin (IL)-1 receptor (1, 2). On ligation, TLR signaling triggers the expression of proinflammatory cytokines, chemokines, and costimulatory and adhesion molecules, leading to the priming of the adaptive immune system and initiation of inflammatory responses (3–5). Expression of TLRs is induced by microbial invasion and microbial components (6, 7). To date, the mammalian TLR family is known to consist of 11 members (TLR1-TLR11), each having specificity to various bacterial, fungal, and viral elements (6, 8). Furthermore, self molecules including heat shock proteins, DNA/RNA from dying cells, fibronectin fragments, and fibrinogen released in response to stress, tissue damage, and cell death have all been shown to act as ligands for a number of TLRs (8). Cytokines such as IFNγ, tumor necrosis factor (TNF)-α, interleukins (IL-1β, IL-2, and IL-5), and growth factors have thus far been implicated in either increased or decreased TLR expression in various cell types. More specifically, IFNγ and TNF have been shown to induce the expression of TLR-2 and TLR-4 in renal epithelium (9).

TLR triggering has been linked in the past to excessive programmed cell death through the production of various cytokines. Recent studies have, however, suggested a direct relationship between TLR-4 and apoptosis, showing that stimulation of overexpressed TLR-4 promoted death in epithelial cells. A dominant-negative mutant of a Fas-associated death domain protein could suppress TLR-4–mediated cell death, indicating that TLR-4 may directly induce apoptosis through a Fas-associated death domain protein–dependent pathway (10–12).

Myelodysplastic syndromes (MDS) constitute a heterogeneous family of clonal disorders of the hematopoietic progenitor cell, predominantly displaying ineffective hematopoiesis and peripheral cytopenias (13). The cause of cytopenias, in at least one subset of MDS patients, has been attributed to an excessive cytokine-induced intramedullary apoptotic death (14, 15). The levels of several cytokines or ligands, known to have proapoptotic and inflammatory properties such as IL-1β, TNF, and Fas
ligand, are elevated in myelodysplastic bone marrow (16–20). This elevated expression has been implicated in increased apoptosis and inhibition of hematopoiesis. It has been hypothesized that TNF primes bone marrow CD34+ cells for Fas-induced apoptosis, suggesting a Fas-Fas ligand interaction as a possible pathogenetic mechanism contributing to immune destruction of CD34+ cells in human myelodysplasia (17).

Taking into consideration mounting evidence supporting the involvement of TLRs in the apoptotic process, we reasoned that measurement of TLR expression levels and their functional ability in MDS-derived cells could provide a further insight into the pathophysiologic events leading to increased apoptosis.

**Materials and Methods**

**Patient characteristics.** Twenty-one newly diagnosed, primary MDS patients were enrolled in the study. The patients were classified according to the WHO criteria and further categorized consistent with the International Prognostic Scoring System (IPSS; Table 1; ref. 13). Twenty uncomplicated iron deficiency anemia patients (9 females and 11 males) were used as controls. None of the patients or controls had experienced microbial infection at least 6 months before the bone marrow aspiration. Informed consent was obtained from all participants in accordance with the regional Hospital Ethical Committee.

**Specific reagents.** Phycoerythrin-conjugated human anti–TLR-4 (clone HTA125) and anti–TLR-2 (clone TL2.1) were sourced from eBioscience (San Diego, CA) and immunoglobulin G (IgG; isotype control) monoclonal antibody was acquired from Santa Cruz Biotechnology (Santa Cruz, CA). FITC-conjugated human antibodies against CD41, CD71, CD33, CD14, CD20, CD3, and Annexin V, as well as phycoerythrin-conjugated antibody against human intercellular adhesion molecule-1 (ICAM-1), were obtained from Becton Dickinson (San Jose, CA). LPS (E. coli, serotype O55:B5) was purchased from Sigma (St. Louis, MO). To ensure the specific function of the chimeric anti-TNF antibody (infliximab), we used total human IgG and a mouse IgG antibody as controls. Titration experiments were done to determine the optimal concentration and induction time of all the reagents used in the experimental protocols.

**Bone marrow mononuclear cell and CD34+ cell isolation and THP-1 cell cultures.** Bone marrow mononuclear cells (BMMC) were isolated from fresh bone marrow samples by density gradient centrifugation using Ficoll Hypaque (specific gravity, 1.077 g/dL; Amersham Bioscience, Uppsala, Sweden). CD34+ cells were obtained by immunomagnetic separation on Mini Macs columns (Miltenyi Biotec, Inc., Gladbach, Germany), with purity >95% as assessed by flow cytometry. The neoplastic peripheral blood monocytic cell line THP-1, used as positive control, was cultured in RPMI 1640 (Life Technologies, Inc., Grand Island, NY) supplemented with 10% fetal bovine serum, 5 × 10^{-5} mol/L 2-mercaptoethanol, 2 mmol/L L-glutamine, 100 units/mL penicillin, and 100 μg/mL streptomycin.

**TLR mRNA analysis.** TLR-1 to TLR-4 mRNA expression was examined in patients, controls, and THP-1 cells. Total RNA was extracted from BMMCs, CD34+ cells, and THP-1 cells using Trizol RNA isolation kit (Invitrogen Life Technologies, Carlsbad, CA) and immunoglobulin G (IgG; isotype control) monoclonal antibody was acquired from Santa Cruz Biotechnology (Santa Cruz, CA). FITC-conjugated human antibodies against CD41, CD71, CD33, CD14, CD20, CD3, and Annexin V, as well as phycoerythrin-conjugated antibody against human intercellular adhesion molecule-1 (ICAM-1), were obtained from Becton Dickinson (San Jose, CA). LPS (E. coli, serotype O55:B5) was purchased from Sigma (St. Louis, MO). To ensure the specific function of the chimeric anti-TNF antibody (infliximab), we used total human IgG and a mouse IgG antibody as controls. Titration experiments were done to determine the optimal concentration and induction time of all the reagents used in the experimental protocols.

**Table 1. Demographic, clinical, and hematologic characteristics of patients**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age/sex</th>
<th>WHO</th>
<th>Hemoglobin (g/dL)</th>
<th>Neutrophil (10^3/mm^3)</th>
<th>Platelet (10^3/mm^3)</th>
<th>IPSS</th>
<th>Karyotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>76/F</td>
<td>RA</td>
<td>9.5</td>
<td>3.5</td>
<td>240</td>
<td>Int-1</td>
<td>46XX</td>
</tr>
<tr>
<td>2</td>
<td>88/M</td>
<td>RAEB-I</td>
<td>8.4</td>
<td>0.5</td>
<td>82</td>
<td>Int-2</td>
<td>Inv 9</td>
</tr>
<tr>
<td>3</td>
<td>72/M</td>
<td>RAEB-II</td>
<td>8.5</td>
<td>0.6</td>
<td>40</td>
<td>High</td>
<td>2q–, 7q–, 18–</td>
</tr>
<tr>
<td>4*</td>
<td>71/M</td>
<td>RAEB-I</td>
<td>5.6</td>
<td>0.8</td>
<td>16</td>
<td>High</td>
<td>46XX</td>
</tr>
<tr>
<td>5</td>
<td>79/M</td>
<td>RAEB-I</td>
<td>7.1</td>
<td>0.3</td>
<td>50</td>
<td>Int-2</td>
<td>46XX</td>
</tr>
<tr>
<td>6*</td>
<td>88/M</td>
<td>RAEB-I</td>
<td>7.4</td>
<td>0.4</td>
<td>60</td>
<td>Int-2</td>
<td>46XX</td>
</tr>
<tr>
<td>7*</td>
<td>80/F</td>
<td>RA</td>
<td>10.0</td>
<td>2.7</td>
<td>168</td>
<td>Int-1</td>
<td>46XX</td>
</tr>
<tr>
<td>8*</td>
<td>78/F</td>
<td>RAEB-II</td>
<td>8.0</td>
<td>0.1</td>
<td>10</td>
<td>High</td>
<td>7</td>
</tr>
<tr>
<td>9*</td>
<td>78/M</td>
<td>RA</td>
<td>8.0</td>
<td>2.5</td>
<td>80</td>
<td>Int-1</td>
<td>46XX</td>
</tr>
<tr>
<td>10*</td>
<td>65/F</td>
<td>RA</td>
<td>10.5</td>
<td>2.7</td>
<td>230</td>
<td>Int-1</td>
<td>46XX</td>
</tr>
<tr>
<td>11*</td>
<td>75/M</td>
<td>RA</td>
<td>10.9</td>
<td>3.4</td>
<td>270</td>
<td>Low</td>
<td>46XX</td>
</tr>
<tr>
<td>12*</td>
<td>72/F</td>
<td>RAEB-I</td>
<td>8.9</td>
<td>2.0</td>
<td>90</td>
<td>Int-2</td>
<td>20q–, 8+</td>
</tr>
<tr>
<td>13</td>
<td>70/F</td>
<td>RCMRD</td>
<td>7.4</td>
<td>2.0</td>
<td>68</td>
<td>Int-1</td>
<td>46XX</td>
</tr>
<tr>
<td>14*</td>
<td>56/F</td>
<td>RA</td>
<td>9.0</td>
<td>7.0</td>
<td>352</td>
<td>Low</td>
<td>46XX</td>
</tr>
<tr>
<td>15*</td>
<td>71/M</td>
<td>RAEB-II</td>
<td>8.7</td>
<td>1.8</td>
<td>56</td>
<td>High</td>
<td>Inv 9</td>
</tr>
<tr>
<td>16*</td>
<td>68/F</td>
<td>RA</td>
<td>8.0</td>
<td>3.6</td>
<td>230</td>
<td>Int-1</td>
<td>46XX</td>
</tr>
<tr>
<td>17*</td>
<td>80/M</td>
<td>RCMRD</td>
<td>8.0</td>
<td>0.7</td>
<td>82</td>
<td>Int-1</td>
<td>46XX</td>
</tr>
<tr>
<td>18*</td>
<td>73/F</td>
<td>RAEB-I</td>
<td>9.7</td>
<td>2.5</td>
<td>100</td>
<td>Int-2</td>
<td>8+</td>
</tr>
<tr>
<td>19*</td>
<td>65/M</td>
<td>RCMRD</td>
<td>10.5</td>
<td>2.9</td>
<td>120</td>
<td>Low</td>
<td>46XX</td>
</tr>
<tr>
<td>20*</td>
<td>65/F</td>
<td>RAEB-I</td>
<td>9.0</td>
<td>3.5</td>
<td>353</td>
<td>Int-2</td>
<td>46XX</td>
</tr>
<tr>
<td>21*</td>
<td>72/F</td>
<td>RAEB-I</td>
<td>6.2</td>
<td>1.2</td>
<td>67</td>
<td>High</td>
<td>5q–, 8+</td>
</tr>
</tbody>
</table>

*Patients studied by flow cytometry.

**Table 2. Characteristics of primer sets and PCR used to detect 18s rRNA and TLRs**

<table>
<thead>
<tr>
<th>Target gene</th>
<th>Accession no.</th>
<th>Amplicon position</th>
<th>Amplicon size</th>
<th>Amplification efficiency</th>
</tr>
</thead>
<tbody>
<tr>
<td>18S rRNA</td>
<td>NG 002801</td>
<td>1,151-1,453</td>
<td>302</td>
<td>1.98</td>
</tr>
<tr>
<td>TLR-1</td>
<td>NM_003263</td>
<td>1,829-2,117</td>
<td>289</td>
<td>1.94</td>
</tr>
<tr>
<td>TLR-2</td>
<td>NM_003264</td>
<td>1,759-2,102</td>
<td>344</td>
<td>1.96</td>
</tr>
<tr>
<td>TLR-3</td>
<td>NM_0032635</td>
<td>2,407-2,771</td>
<td>362</td>
<td>1.87</td>
</tr>
<tr>
<td>TLR-4</td>
<td>NM_003266</td>
<td>3,035-3,370</td>
<td>355</td>
<td>1.91</td>
</tr>
</tbody>
</table>
Paisley, United Kingdom), and 1 μg was reverse transcribed into cDNA using the Promega reverse transcription-PCR kit (Promega, Madison, WI) and oligo-dT primers according to the manufacturer’s instructions. Real-time PCR was used to confirm the integrity and to carry out the normalization of all cDNA samples through the amplification of the 18S rRNA, which served as the housekeeping gene.

Quantitative real-time PCR. TLR mRNA levels were quantified by real-time PCR that was done on a LightCycler system (Roche Molecular Biochemicals, Mannheim, Germany). We designed oligonucleotide primers for each mRNA, consistent with the published sequences (Table 2). Absolute quantification with the use of SYBR Green I dye and standard curves was applied as previously described (21).

Flow cytometry. TLR protein expression in BMMCs and CD34+ cells, as well as in THP-1 cells, was examined by flow cytometry analysis, either constitutively or after the appropriate stimulation. Flow cytometry analysis incorporated 16 of the MDS patients (6 RA, 2 RCDMD, 5 RAEB-I, and 3 RAEB-II) but, for homogeneity reasons, only 8 of the low/Int-1 patients (6 RA and 2 RCDMD) entered the apoptosis protocol (Table 1). Dual staining was applied using antibodies against cell lineage–specific markers [megakaryocytes (CD41), erythroid cells (CD71), myeloid precursors (CD33), monocytic lineage (CD14), B lymphocytes (CD20), and T lymphocytes (CD3)] and TLR-4 or TLR-2 to evaluate the presence and distribution of the two receptors in each bone marrow hematopoietic differentiation compartment. Apoptosis was measured in BMMCs and CD34+ cells by dual staining with TLR-4-phycocerythrin and Annexin V-FITC antibodies. Cells were analyzed using a FACSCalibur flow cytometer and CELLQuest software (Becton Dickinson) with appropriate forward and side scatter adjustments. The results of single staining were evaluated both as mean fluorescence intensity and positive percentage of the total population with comparable results. Dual staining was evaluated as positive percentage of the total population.

Functional assessment of TLRs. TLR-4 ability to recognize LPS (TLR-4 ligand) and induce up-regulation of self mRNA and protein expression, as well as ICAM-1 protein expression, was examined. BMMCs and CD34+ cells from MDS patients and controls, as well as THP-1 cells, were exposed to serum-free medium alone or serum-free medium containing 1 μg/mL LPS. The implication of LPS in the apoptosis of MDS cells was also assessed by Annexin V assay, both constitutively and after LPS and anti-TNF modulation. To evaluate the TNF implication in both TLR-4 and ICAM-1 expression, as well as in the constitutive or LPS-induced apoptosis, MDS BMMCs and THP-1 cells were exposed to serum-free medium alone or serum-free medium containing recombinant human TNF (200 IU/mL), anti-TNF antibody (infliximab; 10 μg/mL), and concurrent LPS and anti-TNF antibody.

Statistical analysis. Continuous variables were compared using the Mann-Whitney U test. Ordered categorical variables were correlated using Spearman’s ρ. Significance was set to 0.05. Stata V8 was used for analysis.

Results

TLR-2 and TLR-4 expression in BMMCs and CD34+ MDS cells. We first examined the expression of TLR-1, TLR-2, TLR-3, and TLR-4 mRNA by reverse transcription-PCR (data not shown) and quantitative real-time PCR. We observed that although TLR-1, TLR-2, TLR-3, and TLR-4 mRNA were found in both MDS and control patients, MDS BMMCs had significantly higher levels of TLR-1 (P < 0.001), TLR-2 (P < 0.001), and TLR-4 mRNA (P < 0.001; Fig. 1A). TLR-3 mRNA was found to be low in BMMCs of both patients and controls. Interestingly, when the CD34+ subset was examined, MDS patients displayed significantly higher levels of TLR-4 mRNA compared with controls (P < 0.001) whereas no statistically significant difference was noted in levels of TLR-1 and TLR-2 (Fig. 1B). This indicates that overexpression of TLR-1 and TLR-2 in BMMCs is the result of their overexpression in the CD34+ compartment. Flow cytometric analysis revealed that MDS BMMCs expressed 19 ± 2.7% higher levels of TLR-4 protein and 14 ± 2.2% TLR-2 protein compared with controls (P < 0.01), a finding consistent with mRNA expression studies.
Moreover, in MDS CD34+ cell population, TLR-4 protein levels were increased by 92% compared with controls (P < 0.01).

TLR-4 and TLR-2 protein expression was also evaluated in CD34+/CD0 bone marrow cells both in patients and controls. Compared with controls, TLR-2 and TLR-4 expression in MDS patients was significantly up-regulated (P < 0.01) in almost all bone marrow cell populations examined, including megakaryocytes, erythroid cells, myeloid precursors, monocytes, and B lymphocytes (Fig. 2A and B). The highest increase in TLR-4- and TLR-2-positive cells was observed in megakaryocytes (30% and 29%, respectively) whereas T lymphocytes were the only population showing no significant increase in the expression of these receptors in comparison with controls. The mean values of the percentage of TLR-2- and TLR-4-positive cells in each specific cell lineage in patients and controls are presented in Table 3.

To examine whether TLR expression correlates with disease severity, we evaluated its expression in two groups, one consisted of low/Int-1 IPSS patients and the other of high/Int-2 patients. Neither group presented any statistically significant variation of TLR expression in either BMMCs or CD34+ cells. The protein expression of TLR-4 and TLR-2 on erythroid cells was inversely correlated with hemoglobin levels (ρ = −0.53, P = 0.034 and ρ = −0.53, P = 0.03, respectively). In addition, the protein expression of TLR-4 on monocytes was inversely correlated with hemoglobin (ρ = −0.60, P = 0.01), neutrophil (ρ = −0.76, P = 0.001), and platelet (ρ = −0.67, P = 0.004) levels.

TLR-4 is functional and capable of up-regulating its own expression. To assess whether TLR-4 is functional and capable of signaling, we used LPS to activate BMMCs. We found that LPS up-regulated ICAM-1, a surrogate marker for TLR-4-mediated activation, in a time- and dose-dependent manner (data not shown). LPS-mediated ICAM-1 induction was comparable between MDS patients and controls [13.7-fold (± 1.7) versus 11.4-fold (± 1.1), respectively]. In THP-1 cells, ICAM-1 expression increased by 82.2-fold (± 8.8). We also

Table 3. Mean values of the percentage of positive cells from all samples examined in the study

<table>
<thead>
<tr>
<th></th>
<th>TLR-4</th>
<th></th>
<th>TLR-2</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>MDS</td>
<td>% Increase</td>
<td>Control</td>
</tr>
<tr>
<td>CD41</td>
<td>14 ± 3%</td>
<td>44 ± 8%</td>
<td>30</td>
<td>10 ± 3%</td>
</tr>
<tr>
<td>CD71</td>
<td>14 ± 3%</td>
<td>27 ± 6%</td>
<td>13</td>
<td>8 ± 25%</td>
</tr>
<tr>
<td>CD33</td>
<td>10 ± 4%</td>
<td>32 ± 6%</td>
<td>22</td>
<td>6 ± 2%</td>
</tr>
<tr>
<td>CD14</td>
<td>35 ± 3%</td>
<td>55 ± 10%</td>
<td>20</td>
<td>25 ± 4%</td>
</tr>
<tr>
<td>CD20</td>
<td>1 ± 1%</td>
<td>25 ± 5%</td>
<td>24</td>
<td>1 ± 1%</td>
</tr>
<tr>
<td>CD3</td>
<td>18 ± 3%</td>
<td>20 ± 6%</td>
<td>2</td>
<td>18 ± 4%</td>
</tr>
</tbody>
</table>
found that LPS powerfully up-regulated the expression of its receptor (TLR-4) with optimal TLR-4 mRNA expression being observed after 12 h of stimulation with 1.0 μg/mL LPS. LPS increased TLR-4 mRNA levels by 24 ± 10% in MDS BMMCs and by 30 ± 10% in control BMMCs when compared with unstimulated cells. Similarly, LPS up-regulated TLR-4 mRNA levels by 90 ± 20% in MDS CD34+ cells and by 70 ± 20% in control CD34+ cells. With regard to protein levels, after 24-h incubation, LPS led to a 520 ± 70% increase of TLR-4 protein expression in BMMCs derived from MDS patients and a 340 ± 50% induction in BMMC from controls. THP-1 cells also revealed a 150 ± 20% increase in TLR-4 protein levels following addition of LPS (Fig. 3).

**TLR-4 constitutive and LPS-induced levels are TNF mediated.**
There is evidence that TLRs are regulated by cytokines such as TNF, IFNγ, interleukins (IL-1β, IL-2, and IL-5), and growth factors. We therefore examined whether TNF regulates TLR-4 expression. We found that TNF up-regulated cell-surface TLR-4 by 170 ± 30% in MDS BMMCs. Interestingly, constitutive TLR-4 levels were also found to be TNF dependent as the addition of infliximab, an anti-TNF monoclonal antibody, reduced TLR-4 levels by 80 ± 20% in MDS BMMCs and 100% in THP-1. LPS stimulation with simultaneous blockade of TNF-mediated pathways showed a decrease in TLR-4 levels of 75 ± 10% and 91 ± 5% in MDS BMMCs and THP-1, respectively (Fig. 3).

**Apoptosis of BMMCs after LPS, TNF, and anti-TNF treatment.**
Apoptosis was monitored by Annexin V binding assay constitutively or after addition of LPS, TNF, anti-TNF, and concurrent LPS and anti-TNF treatment. Constitutively the level of apoptosis after resting in serum-free medium for 24 h was found to be 10 ± 2.5% and 12 ± 1.6% of the total BMMC population in MDS and THP-1 cells, respectively, increasing to 27 ± 4.7% and 42 ± 2.9% (P < 0.001) after LPS triggering. The addition of TNF also resulted in a statistically significant increase of apoptosis reaching 19 ± 3.1% (P < 0.001) and 18 ± 2.0% (P < 0.001) in BMMCs and THP-1, respectively. After anti-TNF treatment, however, the levels of apoptosis decreased in comparison with the constitutive levels in the two cell types (9 ± 1.7% and 8 ± 0.4%, respectively). Finally, concurrent LPS induction and TNF blockade impelled the apoptotic levels to 22.1 ± 3.1% (P < 0.001) and 35.0 ± 2.7% (P < 0.001), revealing statistically significant reductions when compared with the LPS-driven apoptotic levels (Fig. 4).

**TLR-4 expression correlates with apoptotic cell death of CD34+ cells and BMMCs.**
To determine whether TLR-4 expression is correlated with the apoptosis of BMMCs and CD34+ cells of MDS patients, we used the Annexin V binding assay. Due to the excessive heterogeneity of the high/Int-2 MDS subcategory, only low/Int-1 patients were evaluated. In eight of these patients, 5.4 ± 1% of CD34+ cells were found to be Annexin V− compared with 0.5 ± 0.4% in controls. The Annexin V−/TLR-4+ MDS CD34+ cells were 5.2 ± 1%, indicating that 96 ± 4% of apoptotic cells express TLR-4 and 71 ± 6% of the TLR-4+ cells are apoptotic. In controls, only 8% of the apoptotic cells were TLR-4+ (Fig. 5). Similarly, in BMMCs, we found that 10 ± 3% of the resting cells were Annexin V− and 8.3 ± 2% Annexin V−/TLR-4+, indicating that 82 ± 6% of apoptotic cells express TLR-4 and 73 ± 8% of the TLR-4+ cells are apoptotic (Fig. 5). Addition of LPS significantly increased apoptotic Annexin V− cells to 27 ± 5% (P < 0.001) and Annexin V−/TLR-4+ cells to 24.6 ± 4% of the total BMMC population. TNF treatment increased the number of both Annexin V− and TLR-4+ BMMCs without affecting the percentage of Annexin V−/TLR-4+ cells (8.5 ± 2%).

**Discussion**

To our knowledge, this report is the first to show that TLRs are abundantly expressed in the bone marrow of MDS patients. TLR-2 and TLR-4 are found in almost all cell lineages examined,
including megakaryocytes, erythroid cells, myeloid precursors, monocytic lineage, and B lymphocytes, and are significantly up-regulated in MDS patients when compared with controls. TLR-2 and TLR-4 were also detected in CD34+ but, in contrast to other lineages, only TLR-4 was found to be significantly up-regulated in these cells. In addition, the up-regulated ICAM-1 expression by LPS indicates that TLR-4 is equally capable of signaling in MDS hematopoietic cells as in control cells. The higher expression of functional TLR-4 in patients reinforces the likelihood of its involvement in the pathogenesis of MDS because its aberrant increase is present not only in the differentiated cell types but also in the pathophysiologically important CD34+ cell population.

Cytokines (TNF), growth factors, and endogenous ligands can all regulate TLR expression. We found that in MDS BMMCs, TLR-4 expression is TNF dependent as the addition of infliximab, an anti-TNF monoclonal antibody, strongly reduced both constitutive and LPS-induced TLR-4 levels, whereas the addition of TNF strongly up-regulated TLR-4 levels by severalfold. It is worth noting that TNF blockade seemed to result in almost total TLR-4 inhibition. To our knowledge, this is the first time that anti-TNF antibodies have been shown to inhibit TLR-4 expression.

Aberrant TNF mRNA and protein expression has previously been found in MDS patients’ bone marrow, and local cytokine production has been reported to correlate with the levels of intramedullary apoptosis (19, 20), expression of Fas antigen on blasts cells, and disease severity (22, 23). Although the pathophysiologic basis and the origin of TNF production in MDS remain unclear, its documented elevated expression in MDS bone marrow could explain the overexpression of TLR-4 on CD34+ and on differentiated myeloid cells. Therefore, the increase in TLR-2 or TLR-4 expression can possibly be attributed to the elevated TNF and other cytokine production, although other factors, such as increased apoptosis, characterizing the syndrome cannot be excluded. It is known that MDS cells carry a number of genetic alternations that may affect the function of transcription factors (e.g., interferon regulatory factor-1 exon skipping; ref. 21) and, consequently, TLR and other gene expression.

Notably, TLR-4 expression correlates with the extent of apoptosis in bone marrow cells. MDS CD34+ cells presented an ~5-fold and 2-fold increase in apoptosis and TLR expression, respectively. The TLR-4+/Annexin V+ cell percentage in CD34+ control cells increased from 8% to 96% in MDS cells. A strong correlation between apoptosis and increased TLR-4 expression

including megakaryocytes, erythroid cells, myeloid precursors, monocytic lineage, and B lymphocytes, and are significantly up-regulated in MDS patients when compared with controls. TLR-2 and TLR-4 were also detected in CD34+ but, in contrast to other lineages, only TLR-4 was found to be significantly up-regulated in these cells. In addition, the up-regulated ICAM-1 expression by LPS indicates that TLR-4 is equally capable of signaling in MDS hematopoietic cells as in control cells. The higher expression of functional TLR-4 in patients reinforces the likelihood of its involvement in the pathogenesis of MDS because its aberrant increase is present not only in the differentiated cell types but also in the pathophysiologically important CD34+ cell population.

Cytokines (TNF), growth factors, and endogenous ligands can all regulate TLR expression. We found that in MDS BMMCs, TLR-4 expression is TNF dependent as the addition of infliximab, an anti-TNF monoclonal antibody, strongly reduced both constitutive and LPS-induced TLR-4 levels, whereas the addition of TNF strongly up-regulated TLR-4 levels by severalfold. It is worth noting that TNF blockade seemed to result in almost total TLR-4 inhibition. To our knowledge, this is the first time that anti-TNF antibodies have been shown to inhibit TLR-4 expression.

Aberrant TNF mRNA and protein expression has previously been found in MDS patients’ bone marrow, and local cytokine production has been reported to correlate with the levels of intramedullary apoptosis (19, 20), expression of Fas antigen on blasts cells, and disease severity (22, 23). Although the pathophysiologic basis and the origin of TNF production in MDS remain unclear, its documented elevated expression in MDS bone marrow could explain the overexpression of TLR-4 on CD34+ and on differentiated myeloid cells. Therefore, the increase in TLR-2 or TLR-4 expression can possibly be attributed to the elevated TNF and other cytokine production, although other factors, such as increased apoptosis, characterizing the syndrome cannot be excluded. It is known that MDS cells carry a number of genetic alternations that may affect the function of transcription factors (e.g., interferon regulatory factor-1 exon skipping; ref. 21) and, consequently, TLR and other gene expression.

Notably, TLR-4 expression correlates with the extent of apoptosis in bone marrow cells. MDS CD34+ cells presented an ~5-fold and 2-fold increase in apoptosis and TLR expression, respectively. The TLR-4+/Annexin V+ cell percentage in CD34+ control cells increased from 8% to 96% in MDS cells. A strong correlation between apoptosis and increased TLR-4 expression...
was also noted in MDS BMMCs. Furthermore, LPS triggering led to significantly increased apoptotic Annexin V+ and Annexin V+/TLR-4+ cells. Studies indicating that blockage of TLR signaling could reduce apoptosis in MDS cells may strengthen the conclusion that TLR-4 signaling contributes to increased apoptosis in MDS, providing a direct link between TLR-4 function and CD34+ cell apoptosis.

Given the TNF elevated levels in MDS, the aptitude of TNF to induce TLR-4 expression, and the implication of TLR-4 in apoptosis, we suggest that increased TLR-4 expression may participate in MDS extensive apoptosis. However, the marked reduction in TLR-4 expression by anti-TNF was not associated with significant reduction in apoptosis, suggesting that a variety of other apoptotic mechanisms could also be responsible for the increased apoptosis in MDS.

What may trigger TLR signaling in MDS is as yet unknown. In addition to LPS, TLR-4 has been shown to recognize endogenous ligands such as heat shock proteins (HSP60 and HSP70), the extra domain A of fibronectins, oligosaccharides of hyaluronic acid, heparan sulfate, and fibrinogen (3, 5, 24, 25).

All such ligands can be released in response to a variety of stressful conditions, such as heat shock, UV radiation, or increased cell death, activating several cell types including macrophages and dendritic cells to secrete inflammatory cytokines, thereby promoting tissue damage and further cell death. Indeed, HSP60 has been shown to accelerate the activation of procaspases by cytochrome c and the caspase cascade (26). Overexpression of HSP90 has also been shown to increase the rate of apoptosis (27). Whether heat shock proteins or other endogenous TLR ligands activate TLR-4 in MDS remains to be determined.

Our study is the first to suggest that TLR-4 is up-regulated in MDS patients through a TNF-dependent mechanism and is also involved in mediating apoptosis of BMMCs. Further studies are warranted to investigate the implication of the innate immune system through TLR-4 in the pathogenesis of MDS.

Acknowledgments

We thank Dr. M.N. Manoussakis for his valuable suggestions.

References

Toll-like Receptor-4 Is Up-Regulated in Hematopoietic Progenitor Cells and Contributes to Increased Apoptosis in Myelodysplastic Syndromes

Christos I. Maratheftis, Evangelos Andreakos, Haralampos M. Moutsopoulos, et al.